u/tove_ogunleye

Kept the label from every vial.

Agreed — and the follow-up question is what the beyond-use date is based on.

Four observations is not a distribution. The lane tables here only became predictive once individual routes had a dozen or more reports behind them.

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

chromatogram or it did not happen

Keep every transaction hash in a note file with the order reference. It has resolved two queries instantly.

the supplier cannot reverse it and neither can you

Published reimbursement criteria exist in most member states and are usually available in the national language.

vikram_asante is right about cross-border recognition being narrower than the summaries suggest.

7 days on a lane quoted at 7 is the shape you want

Push back: an unconfirmed transaction is not a missing payment. Wait for confirmations before escalating.

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

the lot on the vial has to match the lot on the page

water content is on there and everyone skips it

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

Correction: that was clearance time, not carrier time. The lane table separates them for exactly this reason.

Did you ask for the batch-specific document, or is this the catalogue one?

axis labels included, always

Sent one vial to Janoshik and VendorInvestigate. 99.6% and a claimed 99.0%. Cost me more than the vial and I would do it again.

batch number, date of analysis, method, individual impurities — that is the minimum set

Same lane in a different season for comparison?

That is the quoted lead time, not the observed transit. Both belong in the report and they are different columns.

Total transit decomposes into first mile, international leg, clearance and last mile. Only the first two are meaningfully under the shipper’s control and most reported variance sits in the last two.

Is that intention-to-treat or completers?

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Agreed.

Agreed — and the decomposition matters. Most people are blaming the international leg for a last-mile problem.

redact your own name, never the batch details

the related substances line is where the story is

discontinuation rate is a result, not a footnote

Right, and net peptide content is where the counterion and the water go. Both numbers can be honest and very different.

Careful — the supplier does not control the last mile and most of your variance is in it.

confirmations are the only status that means anything

This. Area percent answers "what fraction of what the detector saw was the peak I wanted", and people read it as "how much peptide is in the vial".

FLOW was kidney outcomes and it is the one nobody quotes

the pharmacy and the prescriber are two separate questions

Push back: an open-label extension tells you about the people who stayed. That is a different question.

Which trial, and which arm?

check who the comparator was before you compare anything